Innate Immunotherapeutics Ltd

New therapeutics from unique technology
activating innate immune signaling

Along with discovery, biotech success often turns on prioritising precious resources. In mid-2010 Innate Therapeutics, which is developing a novel immune response technology, marked a milestone with a US$550,000 grant from the US National Multiple Sclerosis Society and EMD Serono to begin Phase 2 clinical trials for a potential treatment for the progressive form of Multiple Sclerosis (MS).